Format

Send to

Choose Destination
Mol Pharm. 2017 Mar 6;14(3):908-915. doi: 10.1021/acs.molpharmaceut.6b01130. Epub 2017 Feb 21.

Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with 89Zr-5B1.

Author information

1
Department of Radiology, Memorial Sloan Kettering Cancer Center , New York, New York 10065, United States.
2
MabVax Therapeutics , San Diego, California 92121, United States.
3
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center , New York, New York 10065, United States.

Abstract

CA19.9 is one of the most commonly occurring and highest density antigens in >90% of pancreatic cancers, making it an excellent target for monoclonal antibody (mAb)-based imaging and therapy applications. Preloading of unlabeled antibodies to enhance targeting of a radiolabeled mAb has been previously described both for imaging and radioimmunotherapy studies for other targets. We investigated the effect of preloading with the unmodified anti-CA19.9 antibody 5B1 on the uptake and contrast of the PET tracer 89Zr-5B1 in subcutaneous and orthotopic murine models of pancreatic cancer utilizing Capan-2 xenografts, known to both express CA19.9 and shed antigen into circulation. Biodistribution and PET imaging studies with 89Zr-5B1 alone showed high levels in the liver, spleen, and lymph nodes of mice with subcutaneous Capan-2 tumor xenografts when administered without preinjection of 5B1. When unlabeled 5B1 was administered prior to 89Zr-5B1, the tracer significantly enhanced image contrast and tumor to tissue ratios in the same model, and the improvement was related to the time interval between the injections. Moreover, tumors were clearly delineated in an orthotopic pancreatic cancer model using our optimized approach. Taken together, these data suggest that preloading with 5B1 can improve 89Zr-5B1 imaging of disease in a Capan-2 mouse model and that exploration of preloading may have clinical utility for ongoing clinical investigations.

KEYWORDS:

5B1; CA19.9; PET imaging; pancreatic cancer

PMID:
28191976
PMCID:
PMC5341702
DOI:
10.1021/acs.molpharmaceut.6b01130
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center